Financial health
- Operating income covered interest expense -496.6× in the latest year.
2 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$4M | — | — | -37.7% | -36.5% | — | — | $5M |
| 2024 | — | -$361506 | — | — | -71.8% | -69.8% | — | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$3M | — | — | -68.7% | -64.9% | — | — | $3M |
| Mar '26 | — | -$3M | — | — | -39.0% | -37.5% | — | — | $4M |
| Dec '25 | — | -$3M | — | — | -27.4% | -26.5% | — | — | $5M |
| Sep '25 | — | -$954059 | — | — | -6.7% | -6.6% | — | — | $6M |
| Jun '25 | — | -$60346 | — | — | -19.8% | -7.7% | — | — | — |
| Mar '25 | — | -$137583 | — | — | -37.6% | — | — | — | — |
| Dec '24 | — | -$145939 | — | — | -29.0% | -28.2% | — | — | — |
| Sep '24 | — | -$91166 | — | — | -14.6% | — | — | — | — |
| Jun '24 | — | -$44200 | — | — | -6.2% | — | — | — | — |
| Mar '24 | — | -$80202 | — | — | -61.7% | — | — | — | — |
See the revenue and net-income charts above for Curanex Pharmaceuticals Inc's multi-year trend.
As of FY2025, Curanex Pharmaceuticals Inc reported — of total debt against $5M of cash; operating income covered interest expense -496.6×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.